As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on dapagliflozin 10 mg single-dose film-coated tablets as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic neuropathy. The continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus
[Announcement] HTAC Releases its Advisory on the Call for Nominations for the General Track Assessment for 2024
The Health Technology Assessment Council (HTAC) would like to inform its relevant stakeholders and the general public that it cannot set the schedule for the call for topic nominations for the list of priority HTA topics for 2024 as of February 2023 in light of the HTA Philippines’ transfer from the Department of Health (DOH) continue reading : [Announcement] HTAC Releases its Advisory on the Call for Nominations for the General Track Assessment for 2024
[Announcement] HTAC Releases Its Advisory on the Announcement for the Call for Nominations for the General Track Assessment for 2024
The Health Technology Assessment Council (HTAC) would like to inform its relevant stakeholders and the general public that it cannot set the schedule for the call for topic nominations for the list of priority HTA topics for 2024 as of February 2023 in light of the HTA Philippines’ transfer from the Department of Health (DOH) continue reading : [Announcement] HTAC Releases Its Advisory on the Announcement for the Call for Nominations for the General Track Assessment for 2024